Cancer remains one of the most strong challenges existing in modern medicine as of today, making it necessary to innovate strategies to combat its relentless progression. Out of the many strategies ...
Angiogenesis inhibitors showed no increased risk of arterial dissections or aneurysms in metastatic colorectal cancer patients. The study involved 34,733 patients, with 195 cases matched to 1950 ...
The number of lymph node dissections related to survival of patients with locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy: A single-center study. This is an ASCO Meeting ...
This past February, for example, Sugen, a division of Peapack, NJ-based Pharmacia, announced it was aborting its Phase III colorectal cancer clinical trial of SU5416, as no clinical benefit was found.
FDA has announced it has approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal ...
Angiogenesis inhibitors and cardiovascular outcomes in cancer: Real-world, population-based, matched cohort study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC). The research, conducted by an international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results